Chemistry:Icenticaftor
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | QBW251 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C12H13F6N3O3 |
| Molar mass | 361.244 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Icenticaftor (development code QBW251) is a drug candidate for the treatment of chronic obstructive pulmonary disease (COPD)[1][2] and cystic fibrosis.[3][4] The drug is being developed by Novartis.[5]
Like ivacaftor (which is marketed as Kalydeco), icenticaftor functions by acting as a stimulator of the protein cystic fibrosis transmembrane conductance regulator (CFTR).[5]
References
- ↑ "Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial". International Journal of Chronic Obstructive Pulmonary Disease 15: 2399–2409. 2020. doi:10.2147/COPD.S257474. PMID 33116455.
- ↑ "Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease". Journal of Medicinal Chemistry 64 (11): 7241–7260. June 2021. doi:10.1021/acs.jmedchem.1c00343. ISSN 0022-2623. PMID 34028270.
- ↑ "Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)". Journal of Cystic Fibrosis 20 (2): 250–256. March 2021. doi:10.1016/j.jcf.2020.11.002. PMID 33293212.
- ↑ "Icenticaftor Effective in CF Patients With Certain Mutations, Phase 1/2 Trial Shows". BioNews Services. December 9, 2020. https://cysticfibrosisnewstoday.com/2020/12/09/icenticaftor-effective-in-cf-patients-with-certain-mutations-phase-1-2-trial-shows/.
- ↑ 5.0 5.1 "Icenticaftor – Novartis". Adis Insight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800038702.
 |  |
